Index S&P 500 P/E 36.23 EPS (ttm) 2.36 Insider Own 0.41% Shs Outstand 116.33M Perf Week 3.50%
Market Cap 9.91B Forward P/E 15.90 EPS next Y 5.37 Insider Trans -0.23% Shs Float 115.59M Perf Month -4.79%
Enterprise Value 12.29B PEG 5.13 EPS next Q 1.14 Inst Own 100.06% Short Float 5.29% Perf Quarter -9.31%
Income 285.49M P/S 3.54 EPS this Y -0.81% Inst Trans 0.28% Short Ratio 4.80 Perf Half Y -24.23%
Sales 2.80B P/B 1.31 EPS next Y 10.48% ROA 2.16% Short Interest 6.11M Perf YTD -23.49%
Book/sh 64.95 P/C 9.98 EPS next 5Y 7.06% ROE 3.61% 52W High 129.50 -34.06% Perf Year -30.03%
Cash/sh 8.55 P/FCF 19.80 EPS past 3/5Y -33.21% 3.37%ROIC 2.61% 52W Low 81.36 4.95% Perf 3Y -40.02%
Dividend Est. 0.27 (0.32%) EV/EBITDA 14.63 Sales past 3/5Y -10.38% -0.91% Gross Margin 50.58% Volatility 3.40% 3.14% Perf 5Y -24.74%
Dividend TTM 0.28 (0.33%) EV/Sales 4.39 EPS Y/Y TTM 32.86% Oper. Margin 15.28% ATR (14) 2.92 Perf 10Y 80.34%
Dividend Ex-Date Oct 17, 2025 Quick Ratio 2.75 Sales Y/Y TTM 3.33% Profit Margin 10.20% RSI (14) 45.36 Recom 2.05
Dividend Gr. 3/5Y 0.00% 0.00% Current Ratio 3.33 EPS Q/Q -26.91% SMA20 -2.27% Beta 0.99 Target Price 112.00
Payout 11.63% Debt/Eq 0.45 Sales Q/Q 4.13% SMA50 -5.96% Rel Volume 1.20 Prev Close 85.28
Employees 11000 LT Debt/Eq 0.45 Earnings Jul 28 BMO SMA200 -16.43% Avg Volume 1.27M Price 85.39
IPO Jul 06, 1965 Option/Short Yes / Yes EPS/Sales Surpr. 2.78% 1.34% Trades
Volume 1,523,626 Change 0.13%
Date
Action
Analyst
Rating Change
Price Target Change
May-01-25 Upgrade UBS
Neutral → Buy
$115
Jan-10-25 Downgrade Bernstein
Outperform → Mkt Perform
$130
Dec-13-24 Upgrade BofA Securities
Neutral → Buy
$138
Oct-15-24 Upgrade Barclays
Equal Weight → Overweight
$125 → $140
Aug-28-24 Initiated Wells Fargo
Equal Weight
$130
Jul-08-24 Initiated Leerink Partners
Outperform
$125
Jun-03-24 Resumed Jefferies
Hold
$115
Jan-16-24 Downgrade UBS
Buy → Neutral
$105 → $125
Jan-04-24 Upgrade Evercore ISI
In-line → Outperform
$88 → $125
Dec-19-23 Initiated Wells Fargo
Equal Weight
$95
Dec-13-23 Initiated Wolfe Research
Peer Perform
Sep-28-23 Initiated Bernstein
Outperform
$133
Jul-19-23 Initiated Raymond James
Outperform
$145
May-23-23 Resumed Goldman
Buy
$150
Show Previous Ratings
Sep-12-25 12:35AM
Sep-10-25 04:53AM
Sep-03-25 12:36PM
Sep-02-25 02:26PM
08:00AM
04:32PM
Loading…
Aug-27-25 04:32PM
Aug-18-25 08:00AM
12:02AM
Aug-13-25 12:23AM
12:21AM
Aug-12-25 02:20PM
Aug-06-25 08:00AM
Jul-30-25 09:25AM
Jul-29-25 03:02AM
Jul-28-25 02:15PM
11:51AM
Loading…
11:51AM
11:51AM
10:11AM
09:30AM
07:39AM
07:10AM
06:26AM
06:07AM
(Associated Press Finance)
06:00AM
Jul-26-25 11:04PM
Jul-25-25 12:10PM
Jul-24-25 04:05PM
11:11AM
Jul-23-25 09:15AM
Jul-22-25 10:00AM
10:00AM
Loading…
Jul-21-25 10:00AM
Jul-15-25 09:22AM
Jul-13-25 11:31PM
Jul-11-25 12:03AM
Jul-07-25 08:00AM
Jul-03-25 12:37AM
Jun-30-25 07:20AM
Jun-27-25 10:25AM
Jun-24-25 11:13AM
Jun-05-25 11:31AM
Jun-02-25 08:00AM
May-23-25 10:47AM
May-19-25 05:00PM
08:00AM
May-14-25 04:54PM
May-06-25 12:35AM
May-01-25 12:40AM
Apr-30-25 08:00AM
Apr-29-25 05:57AM
03:02AM
01:20AM
(Thomson Reuters StreetEvents)
Apr-28-25 01:18PM
11:49AM
11:13AM
10:47AM
09:30AM
07:32AM
07:15AM
06:09AM
(Associated Press Finance)
06:06AM
06:00AM
Apr-27-25 03:01AM
Apr-25-25 12:10PM
08:00AM
Apr-24-25 04:05PM
07:45AM
Apr-23-25 10:01AM
Apr-21-25 10:00AM
Apr-10-25 01:31PM
(Morningstar Research) -8.21%
Apr-03-25 08:00AM
05:21AM
Apr-02-25 08:00AM
07:47AM
Mar-21-25 12:53PM
Mar-20-25 08:13PM
01:00PM
Mar-03-25 08:00AM
04:03AM
Feb-28-25 04:08AM
Feb-26-25 08:32AM
Feb-20-25 12:30PM
08:00AM
Feb-18-25 10:18AM
Feb-01-25 02:03AM
12:00AM
(Thomson Reuters StreetEvents)
Jan-31-25 03:48PM
03:10PM
09:30AM
07:10AM
06:19AM
(Associated Press Finance)
06:00AM
Jan-24-25 12:27PM
10:00AM
Jan-23-25 04:05PM
12:10PM
Jan-13-25 04:31PM
08:00AM
Jan-12-25 05:00PM
Jan-10-25 11:37AM
08:00AM
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MICHAS ALEXIS P Director Aug 27 '25 Sale 89.01 500 44,505 7,270 Aug 28 04:05 PM MICHAS ALEXIS P Officer Aug 27 '25 Proposed Sale 88.00 500 44,000 Aug 27 03:29 PM McMurry-Heath Michelle Director May 29 '25 Sale 92.17 600 55,299 4,833 May 30 04:06 PM McMurry-Heath Michelle Director May 29 '25 Proposed Sale 92.17 600 55,299 May 29 02:23 PM McMurry-Heath Michelle Director Feb 06 '25 Sale 119.49 1,970 235,395 3,021 Feb 07 04:05 PM McMurry-Heath Michelle Director Feb 06 '25 Proposed Sale 119.49 1,970 235,395 Feb 06 03:27 PM Goldberg Joel S Please See Remarks Jan 30 '25 Option Exercise 81.29 15,170 1,233,169 48,570 Jan 31 04:05 PM Goldberg Joel S Please See Remarks Jan 30 '25 Sale 126.73 15,170 1,922,513 33,400 Jan 31 04:05 PM Goldberg Joel S Officer Jan 30 '25 Proposed Sale 126.73 15,170 1,922,555 Jan 30 04:05 PM Vohra Tajinder S Please See Remarks Jan 07 '25 Option Exercise 81.29 5,492 446,445 25,144 Jan 08 04:05 PM Vohra Tajinder S Please See Remarks Jan 07 '25 Sale 116.81 5,492 641,543 19,652 Jan 08 04:05 PM Vohra Tajinder S Officer Jan 07 '25 Proposed Sale 116.81 5,492 641,539 Jan 07 04:58 PM Singh Prahlad R. Please See Remarks Dec 02 '24 Option Exercise 81.29 18,365 1,492,891 108,560 Dec 03 04:05 PM Singh Prahlad R. Please See Remarks Dec 02 '24 Sale 116.22 18,365 2,134,366 90,195 Dec 03 04:05 PM Singh Prahlad R. Officer Dec 02 '24 Proposed Sale 115.79 18,365 2,126,483 Dec 02 10:55 AM Vohra Tajinder S Please See Remarks Oct 09 '24 Sale 121.73 2,154 262,202 19,652 Oct 10 04:05 PM Vohra Tajinder S Officer Oct 09 '24 Proposed Sale 121.73 2,154 262,199 Oct 09 04:21 PM Vohra Tajinder S Please See Remarks Oct 08 '24 Sale 122.59 2,154 264,057 21,806 Oct 09 04:05 PM Vohra Tajinder S Please See Remarks Oct 07 '24 Sale 122.09 2,153 262,853 23,960 Oct 09 04:05 PM Vohra Tajinder S Officer Oct 08 '24 Proposed Sale 122.59 2,154 264,066 Oct 08 04:42 PM Vohra Tajinder S Officer Oct 07 '24 Proposed Sale 122.09 2,153 262,855 Oct 07 04:10 PM
